This invention provides methods for the use of substituted indole compounds of the general formula: ##STR00001## and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A.sub.2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.

Wyeth

Methods for the use of inhibitors of cytosolic phospholipase A2

Wyeth LLC

The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.

Eisai R&amp;D Management Co., Ltd.

Method of screening substance useful in treating disease with the use of GPR40 and phospholipase

The invention relates to a human phospholipase C expressed in the brain (B-PLC) and induced in response to ischemic brain tissue. The inventions provides methods and reagents useful for diagnosis and treatment of hypoxic-ischemic brain insult such as stroke.

phospholipase/accident vascular cerebral

Methods for the use of inhibitors of cytosolic phospholipase A2

Methods for the use of inhibitors of cytosolic phospholipase A2

Method of screening substance useful in treating disease with the use of GPR40 and phospholipase

Diagnostic marker for neurological conditions

La base de dades d’herbes medicinals més completa avalada per la ciència